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Introduction: A progressive loss of circulating anti-human epidermal growth factor receptor-2/neu (HER2) CD4+ T-helper
type 1 (Th1) immune responses is observed in HER2pos-invasive breast cancer (IBC) patients relative to healthy controls.
Pathologic complete response (pCR) following neoadjuvant trastuzumab and chemotherapy (T + C) is associated with
decreased recurrence and improved prognosis. We examined differences in anti-HER2 Th1 responses between pCR and
non-pCR patients to identify modifiable immune correlates to pathologic response following neoadjuvant T + C.
Methods: Anti-HER2 Th1 responses in 87 HER2pos-IBC patients were examined using peripheral blood mononuclear cells
pulsed with 6 HER2-derived class II peptides via IFN-γ ELISPOT. Th1 response metrics were anti-HER2 responsivity, repertoire
(number of reactive peptides), and cumulative response across 6 peptides (spot-forming cells [SFC]/106 cells). Anti-HER2
Th1 responses of non-pCR patients (n = 4) receiving adjuvant HER2-pulsed type 1-polarized dendritic cell (DC1)
vaccination were analyzed pre- and post-immunization.
Results: Depressed anti-HER2 Th1 responses observed in treatment-naïve HER2pos-IBC patients (n = 22) did not
improve globally in T + C-treated HER2pos-IBC patients (n = 65). Compared with adjuvant T + C receipt, neoadjuvant
T + C — utilized in 61.5 % — was associated with higher anti-HER2 Th1 repertoire (p = 0.048). While pCR (n = 16) and
non-pCR (n = 24) patients did not differ substantially in demographic/clinical characteristics, pCR patients demonstrated
dramatically higher anti-HER2 Th1 responsivity (94 % vs. 33 %, p = 0.0002), repertoire (3.3 vs. 0.3 peptides, p < 0.0001),
and cumulative response (148.2 vs. 22.4 SFC/106, p < 0.0001) versus non-pCR patients. After controlling for potential
confounders, anti-HER2 Th1 responsivity remained independently associated with pathologic response (odds
ratio 8.82, p = 0.016). This IFN-γ+ immune disparity was mediated by anti-HER2 CD4+T-bet+IFN-γ+ (i.e., Th1) —
not CD4+GATA-3+IFN-γ+ (i.e., Th2) — phenotypes, and not attributable to non-pCR patients’ immune incompetence,
host-level T-cell anergy, or increased immunosuppressive populations. In recruited non-pCR patients, anti-HER2
Th1 repertoire (3.7 vs. 0.5, p = 0.014) and cumulative response (192.3 vs. 33.9 SFC/106, p = 0.014) improved
significantly following HER2-pulsed DC1 vaccination.
Conclusions: Anti-HER2 CD4+ Th1 response is a novel immune correlate to pathologic response following
neoadjuvant T + C. In non-pCR patients, depressed Th1 responses are not immunologically “fixed” and can be restored
with HER2-directed Th1 immune interventions. In such high-risk patients, combining HER2-targeted therapies with
strategies to boost anti-HER2 Th1 immunity may improve outcomes and mitigate recurrence.* Correspondence: brian.czerniecki@uphs.upenn.edu
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Human epidermal growth factor receptor-2 (HER2)/neu
overexpression, a molecular oncodriver in 20–25 % of
breast cancers (BC) [1], is associated with an aggressive
clinical course and poor overall prognosis [2]. The avail-
ability of HER2-targeted therapies (e.g., trastuzumab,
lapatinib, etc.) has dramatically improved outcomes in
patients with HER2-positive (HER2pos) BC [3, 4]. In
contemporary practice, patients with larger resectable
tumors often benefit from neoadjuvant administration
of trastuzumab and chemotherapy (T + C), with nearly
40–60 % achieving pathologic complete response
(pCR) [5–7]; compared with incomplete response
(non-pCR), pCR is associated with decreased recurrence
and improved long-term survival [7, 8]. While absent
estrogen/progesterone receptor (ER/PR) expression appears
to reproducibly correlate with pCR [8, 9], there are a pau-
city of modifiable immune signatures that are associated
with response and/or resistance to neoadjuvant T + C.
Utilizing a prospective cohort, we have recently demon-
strated a progressive loss in anti-HER2 CD4+ T-helper
type-1 (Th1) immunity across a tumorigenesis continuum
in HER2pos BC [10]. Interestingly, HER2-specific Th1 re-
sponses are preserved in healthy volunteers and patients
harboring HER2neg (0–1+) invasive breast cancer (IBC). In
patients with HER2pos IBC, this anti-HER2 Th1 deficit is
not impacted by standard therapies (i.e., surgical resection,
radiation, or T + C treatment), but can be restored follow-
ing HER2-pulsed type-1-polarized dendritic cell (DC1) vac-
cinations. Moreover, depressed anti-HER2 Th1 responses
predict an increased risk of subsequent recurrence in pa-
tients treated with adjuvant T + C [10]. These observations
prompted us to investigate whether similar depressed anti-
HER2 Th1 responses are observed in another known har-
binger of recurrence, non-pCR status following neoadjuvant
T + C [8]; conversely, we hypothesized that preservation/
restoration of anti-HER2 Th1 responses may be associated
with pCR.
In this study, we identified elevated anti-HER2 CD4+
Th1 response as a novel systemic immune correlate to
pCR following neoadjuvant T + C in patients with
HER2pos IBC. Relatively depressed anti-HER2 Th1 re-
sponses in patients with non-pCR are not attributable to
host-level T cell anergy, loss of immunocompetence, or
increase in circulating immunosuppressive phenotypes.
Importantly, this anti-HER2 Th1 deficit in patients with
non-pCR is not fixed, and can be corrected with CD4+
Th1-directed immune manipulations via HER2-targeted
DC1 vaccinations. To the best of our knowledge, these
observations represent the first demonstration of a
modifiable host-level oncodriver (HER2/neu)-specific
immune disparity that is associated with pathologic re-
sponse to neoadjuvant T + C. These findings may have
important implications for immune monitoring and/ordesign of adjunctive immune therapies to improve
outcomes in trastuzumab-treated HER2pos BC patients.
Methods
Study design
After approval by the Institutional Review Board of the
University of Pennsylvania, 87 patients with HER2pos
IBC were enrolled in a non-biased fashion (Table 1). Eli-
gible patients had histologically confirmed IBC, HER2/
neu overexpression (i.e., immunochemistry (IHC) 3+ or
2+/fluorescence in situ hybridization (FISH)-positive)
confirmed at our institution, no evidence of distant
metastasis, and were not receiving immunosuppressive
medications. Informed consent was obtained from all
participants. Anti-HER2 CD4+ Th1 responses of re-
cruited subjects were analyzed prospectively. Anti-HER2
Th1 responses in treatment-naïve (i.e., not receiving de-
finitive therapy at enrollment) stage I–III HER2pos IBC
patients (n = 22) were established as an immunologic
"baseline", and were compared with Th1 responses in
stage I–III HER2pos IBC patients who had completed T
+ C treatment (n = 65; i.e., either neoadjuvant or adju-
vant T + C plus definitive surgery). In patients treated
with T + C, analyses were stratified by sequence of
chemotherapy (i.e., neoadjuvant versus adjuvant), and fur-
ther sub-stratified by pCR and non-pCR status within the
neoadjuvant cohort (Fig. 1). pCR was defined as absence of
residual invasive cancer on pathologic examination of
resected breast specimen(s) and sampled lymph nodes (i.e.,
ypT0/Tis ypN0).
Four patients with non-pCR were recruited to our adju-
vant HER2-pulsed DC1 vaccination trial (NCT02061423);
anti-HER2 Th1 responses in these patients were compared
pre-immunization and post-immunization.
Immune response detection
Circulating anti-HER2 CD4+ Th1 responses were examined
in unexpanded peripheral blood mononuclear cells (PBMC)
pulsed ex vivo with six HER2-derived class II peptides
(42–56, 98–114, 328–345, 776–790, 927–941, 1166–1180
[11]), by measuring IFN-γ production via enzyme-linked
immunosorbent spot (ELISPOT) assays. ELISPOT was
performed as previously described [10, 12]. Briefly,
polyvinylidene fluoride (PVDF) membrane plates
(Mabtech Inc., Cincinnati, OH, USA) were coated with
anti-IFN-γ capture antibody. After plates were blocked,
cryopreserved PBMCs, isolated using density gradient
centrifugation, were plated in triplicate (2 × 105 cells/well)
and incubated at 37 °C for 24–36 h with either HER2 pep-
tides (4 μg; Genscript, Piscataway, NJ, USA); media alone
(unstimulated control); or positive control (anti-
human CD3/CD28 antibodies (0.5 μg/mL; BD Phar-
mingen, San Jose, CA, USA)). After washing, biotinylated
detection antibody (100 μg/mL) and 1:1000-diluted
Table 1 Demographic and tumor-related characteristics of the study population: age, race, AJCC pathologic stage, hormone
receptor status, and time from completion of trastuzumab (when applicable)





Age, years, mean ± standard error 56.8 ± 3.1 45.9 ± 2.1 57.2 ± 2.6
Age, years, range 36–88 24–81 28–85
Race/ethnicity, number (%)
Caucasian 17 (77.3) 35 (87.5) 19 (76.0)
African-American 2 (9.1) 3 (7.5) 4 (16.0)
Asian 2 (9.1) 1 (2.5) 0 (0)
Hispanic 1 (4.5) 1 (2.5) 2 (8.0)
AJCC stage at diagnosisa, number (%)
Stage 1 14 (63.6) 0 (0) 6 (24.0)
Stage 2 6 (27.3) 21 (52.5) 15 (60.0)
Stage 3 2 (9.1) 19 (47.5) 4 (16.0)
Hormone receptor status, number (%)
ER/PRpos 12 (54.5) 18 (45.0) 11 (44.0)
ER/PRneg 10 (45.5) 22 (55.0) 14 (56.0)
Time from completion of trastuzumab to study enrollment, number (%)
<6 months 18 (45.0) 10 (40.0)
≥6 months 22 (55.0) 15 (60.0)
aFor neoadjuvant cohort, AJCC clinical stage is shown. HER2pos Human epidermal growth factor receptor overexpressing, IBC invasive breast cancer, T + C
trastuzumab and chemotherapy, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor
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FCS were added serially, and addition of 3,3′-5,5′ tetra-
methylbenzidin (TMB) substrate solution revealed spot
formation. Spot-forming cells (SFC) were counted using
an automated reader (ImmunoSpot CTL, Shaker Heights,
OH, USA).
PBMC from HLA-A2.1pos donors were stimulated with
two HER2-derived class I peptides (369–377, 689–697)
[11]; phorbol-12-myristate 13-acetate (PMA, 50ng/mL)
and ionomycin (1μg/mL; Sigma-Aldrich, St. Louis, MO,
USA) served as positive control. HLA-A2.1 typing (LAB-
Type® SSO) was performed in the Clinical Immunology la-
boratory at the Hospital of the University of Pennsylvania.
In addition, HER2-specific IL-4 and IL-10 production (sur-
rogates for T-helper type-2 (Th2) and regulatory T-cell
(Treg) cell function, respectively) were measured by
ELISPOT [13]. Recall Th1 responses were examined
by stimulating PBMC with 1:100-diluted recall stim-
uli Candida albicans (Allermed Laboratories, San
Diego, CA, USA) and tetanus toxoid (Santa Cruz Biotech-
nology, Dallas, TX, USA).
An empiric method of determining anti-HER2 Th1
response specificity was employed [10]. A positive response
to an individual HER2 peptide was defined as: (a) threshold
minimum of 20 SFC/2 × 105 cells in experimental wells
after subtracting unstimulated background; and (b) ≥2-foldincrease in antigen-specific SFCs over background. Three
metrics of anti-HER2 Th1 response were defined for each
cohort: (a) responsivity (proportion of patients responding
to ≥1 peptide), (b) repertoire (mean number of reactive
peptides), and (c) cumulative response across 6 peptides
(SFC/106 cells). A sample calculation is illustrated in
Additional file 1: Figure S1. Inter-assay precision of
ELISPOTassays was validated as described previously [14].Flow cytometry
PBMC suspensions were prepared in FACS buffer (PBS + 1
% FCS + 0.01 % azide) and anti-human CD3, CD4, CD8,
CD83, HLA-DR, CD11b, CD33, CD19, CD16 (BD
Bioscience, San Jose, CA, USA), CD4, and CD25 (Bio-
legend, San Diego, CA, USA) were used to determine
the relative PBMC immunophenotype. After washing, cells
were incubated for 30 minutes at room temperature (RT)
with antibody mixtures. Following incubation, cells were
washed/fixed with 2 % paraformaldehyde. Intracellular
staining with anti-FoxP3 (eBioscience, San Diego, CA,
USA) using the FoxP3 fixation/permeabilization kit (Biole-
gend) was performed according to manufacturer’s in-
structions. Analysis was performed using the BD LSR-II
cytometer, and datasets were analyzed using CellQuest
Pro software.
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of the study population. In this study, 87 patients with human epidermal
growth factor receptor 2-positive (HER2pos) breast cancer were enrolled; all tumors were histologically confirmed as invasive breast cancer (IBC)
with HER2 overexpression (3+ or 2+/fluorescence in situ hybridization (FISH)-positive). Cohorts are labeled (a–g) for ease of comparison
(of immune responses), and are referred to in Results. Time points at which blood was drawn are indicated (red callout boxes). Median follow up in the
cohort treated with trastuzumab and chemotherapy (T + C) was 26 (IQR 16.5–31.0) months. pCR pathologic complete response, DCI type 1-polarized
dendritic cell, Adj adjuvant, mo months
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PBMC were resuspended at 1.2 × 106 cells/mL in
DMEM + 5 % human serum in 24-well plates, and pulsed
with HER2-class II peptide mix (24 μg/mL). Unstimulated
and anti-CD3/CD28 antibody-pulsed PBMCs from each
donor served as negative and positive controls, respectively.
Following incubation for 6 h at 37 °C, protein transport in-
hibitor Brefeldin-A (Sigma Aldrich; 10 μg/mL) was added
to each sample, and incubated overnight. Following
washing, cells were stained with anti-CD4 for 30 minutes
at RT. Cells were washed twice, fixed and permeabilized
as described above, and stained with anti-T-bet, anti-
GATA-3 and anti-IFN-γ (Biolegend) for 30 minutes. After
incubation, cells were washed and analyzed using the BD
LSR-II cytometer.Vaccination procedure and trial design
We have initiated a phase I adjuvant HER2-pulsed DC1 vac-
cination trial for patients with HER2pos IBC with residual
disease following neoadjuvant T + C (NCT02061423). Eli-
gible patients are 18 years or older, have Eastern Coopera-
tive Oncology Group (ECOG) performance status score of 0
or 1, and have biopsy-proven stage I–III HER2pos IBC. The
primary endpoint of this trial is safety/feasibility; however,
we report an interim analysis of anti-HER2 immune
responses following vaccination (a secondary endpoint) in
recruited patients (n = 4) as proof of principle of its
immunogenicity in this heavily pre-treated population.
Monocytic dendritic cell precursors (CD14pos peripheral
blood monocytes) were obtained from subjects via tandem
leukapheresis/countercurrent centrifugal elutriation.
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phage serum-free medium (Cellgro, Manassas, VA, USA)
with granulocyte monocyte colony stimulating factor (GM-
CSF, 250 IU/mL; Berlex, San Pablo, CA, USA) and IL-4
(1000 u/mL; R&D Systems, Minneapolis, MN, USA) - these
are considered immature DCs (iDCs). The following day,
iDCs were pulsed with the aforementioned six HER2 major
histocompatability class (MHC)-II promiscuous-binding
peptides (42–56, 98–114, 328–345, 776–790, 927–941,
1166–1180). After 8–12 h incubation, IFN-γ (1000 U/mL)
was added; the following day, National Institutes of
Health (NIH) reference standard lipopolysaccharide
(LPS) was added (10 ng/mL) to achieve full DC activation
to a DC1 phenotype 6 h before harvest. For HLA-A2.1pos
patients, DC1 were pulsed with two MHC class I binding
peptides (369–377, 689–697). Harvested cells were
washed and lot release criteria of >70 % viability, negative
Gram stain, and endotoxin <5 EU/kg confirmed.
Immunizations were administered in the NIH-designated
General Clinical Research Center at the Hospital of
the University of Pennsylvania. Injections comprised
10–20 × 106 HER2-pulsed DC1s suspended in 1 mL
sterile saline, and administered by ultrasound guidance
into groin lymph nodes [12, 15]. Immunizations were
administered once weekly for 6 weeks, followed by three
booster doses spaced 3 months apart.
Statistical analysis
Descriptive statistics summarized distributions of patient
characteristics and immune response variables. Data trans-
formation of the cumulative response variable (natural log
or square root) was applied to meet the assumptions
of parametric testing, where applicable. The unpaired
or paired Student’s t test (parametric continuous data),
Mann–Whitney (non-parametric continuous data), and chi
square (χ2) tests (categorical data) were used for two-group
and univariate comparisons between pCR and non-pCR
cohorts. To determine independent correlates of pCR, vari-
ables with a trend toward significance on univariate testing
(p <0.20) were entered into a forward, stepwise multivari-
able logistic regression model (p <0.05 for entry, p <0.10
for exit). A p value <0.05 was considered statistically
significant. All tests were two-sided. Analyses were per-
formed using Prism 5.0 (GraphPad Inc., La Jolla, CA,
USA) and SPSS version 22 (IBM Corp, Chicago, IL, USA).
Results
Patient characteristics
In the overall cohort (n = 87), mean age was 51.4 ± 1.5
(range 24–88) years and a majority (81.6 %) were white.
Demographic and tumor-related characteristics of partici-
pants are detailed in Table 1. Of the cohort treated
with T + C (n = 65), neoadjuvant T + C was administered
in 40 patients (61.5 %); 16 patients (40.0 %) achieved pCRwhereas 24 (60.0 %) had residual disease at surgery
(non-pCR). Median follow up in patients treated with
T + C was 26 (IQR 16.5–31) months (Fig. 1).
In patients treated with neoadjuvant T + C, mean age
and body mass index (BMI) were 45.9 ± 2.1 years and
32.3 ± 2.1 kg/m2, and a majority were white (87.5 %) or
premenopausal (57.5 %). More than half of patients had
ER/PRneg tumors (55.0 %) or clinical stage II disease at diag-
nosis (52.5 %). Among pathologic features, lymphovascular
invasion (LVI) and nuclear grade 3 were observed in 7 (17.5
%) and 26 (65.0 %) tumors, respectively. The most com-
monly utilized treatment regimen and operative approach
was Adriamycin/Cyclophosphamide/Taxol/Herceptin (AC/
TH; 82.5 %) and mastectomy (67.5 %), respectively.
Depressed anti-HER2 CD4+ responses in treatment-naïve
HER2pos IBC patients are not globally restored
following T + C
Using PBMCs, we compared IFN-γ+ anti-HER2 CD4+
T-cell responses between HER2pos IBC cohorts via HER2-
stimulated IFN-γ ELISPOT. We have previously demon-
strated a striking loss of anti-HER2 Th1 responses in
treatment-naïve HER2pos IBC patients relative to healthy
donors [10]. In the current study, depressed anti-HER2 Th1
responses in treatment-naïve HER2pos IBC patients (cohort
A; Fig. 1) – assessed by responsivity, repertoire, or cumula-
tive response – did not improve globally in HER2pos IBC
patients treated with T + C (cohort B; Fig. 2a). Among T +
C – treated patients, neoadjuvant T + C receipt (cohort D)
was associated with higher anti-HER2 Th1 repertoire (1.5
± 0.3 vs. 0.8 ± 0.4; p = 0.048), but not responsivity or
cumulative response, compared with adjuvant T + C treat-
ment (cohort C; Fig. 2b).
Anti-HER2 T cell immune responses correlate strongly
with pCR
In the cohort receiving neoadjuvant T + C, patients achiev-
ing pCR (cohort E; Fig. 1) demonstrated dramatically higher
IFN-γ+ anti-HER2 Th1 responsivity (93.8 % vs 33.3 %, p =
0.0002), repertoire (3.3 ± 0.3 vs 0.3 ± 0.1, p <0.0001), and
cumulative response (148.2 ± 24.6 vs 22.4 ± 3.0, p <0.0001)
compared with non-pCR patients (cohort F; Fig. 3a). Of
note, median duration from initiation of neoadjuvant T + C
to study enrollment did not differ between pCR and
non-pCR cohorts (23.5 vs 26.5months, p = 0.44).
Evaluable PBMC from HLA-A2.1pos pCR and non-
pCR patients were stimulated ex vivo with two HER2-
derived class I peptides. Compared with non-pCR patients,
IFN-γ+ CD8+ T cell responses were significantly higher in
pCR patients upon stimulation with the immunodominant
HER2369–377 (72.1 ± 10.2 vs 12.1 ± 2.4 SFC/2 × 10
5, p =
0.002) epitope, but not the subdominant HER2689–697
(21.5 ± 3.7 vs 17.3 ± 4.0 SFC/2 × 105, p = 0.47) epitope
(Fig. 3b).
Fig. 2 Interferon (IFN)-γ+ anti-human epidermal growth factor receptor 2 (HER2) CD4+ T cell response variations in HER2pos patients with invasive
breast cancer (IBC). IFN-γ enzyme-linked immunosorbent spot analysis of HER2 peptide-pulsed peripheral blood mononuclear cells examined
anti-HER2 CD4+ T cell responses in patients with HER2pos IBC, stratified by anti-HER2 responsivity, response repertoire (mean # of reactive peptides),
and cumulative response (mean total SFC/106 cells). Differences between (a) Treatment-naïve patients with HER2pos IBC (n = 22) and those treated
with trastuzumab and chemotherapy (T + C) (n = 65); and (b) patients treated with Neoadjuvant T + C (n = 40) and those treated with Adjuvant
T + C (n = 25). SFC spot-forming cells
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with pCR following multivariable analysis
The independent association between IFN-γ+ anti-
HER2 Th1 responses and pCR was evaluated by control-
ling for confounding from relevant demographic and
clinicopathologic characteristics. Upon univariate
testing, pCR and non-pCR cohorts did not differ signifi-
cantly by age, menopausal status, race, BMI, comorbid-
ity, presence of LVI, nuclear grade, or utilized T + C
regimens. However, pCR patients were more likely to
have ER/PRneg tumors compared with patients with
non-pCR (68.8 % vs 29.2 %, p = 0.02). Although pCR
patients demonstrated a trend toward presentation at
lower (i.e., stage II) clinical stage (68.8 % vs 41.7 %, p =
0.12) and less frequent need for mastectomy (50.0 % vs
79.2 %, p = 0.09), these comparisons did not reach statis-
tical significance (Table 2).Relevant clinicopathologic variables on univariate test-
ing (i.e., ER/PR status, clinical stage, operative approach)
and anti-HER2 responsivity (Th1 repertoire and cumula-
tive response were highly co-linear) were entered into a
multivariable logistic regression analysis. Anti-HER2
Th1 responsivity (odds ratio (OR) 8.82, 95 % CI 1.50,
51.83, p = 0.016) and ER/PR status (OR 4.71, 95 %
CI 1.03, 21.58, p = 0.046) remained independently
associated with pCR status.
Due to persistence of the association between ER/PR
status and pCR on multivariable analysis, anti-HER2
Th1 responses were stratified by hormone receptor sta-
tus. No significant differences in anti-HER2 Th1 respon-
sivity (72.2 % vs 50.0 %, p = 0.23), repertoire (1.9 ± 0.4
vs 1.1 ± 0.4, p = 0.12), or cumulative response (80.6 ±
18.7 vs 64.8 ± 20.3, p = 0.57) were observed between ER/
PRneg (n = 22) and ER/PRpos (n = 18) patients, respectively.
Fig. 3 Significant disparity in anti-human epidermal growth factor receptor 2 (anti-HER2) interferon (IFN)-γ+ T cell immune responses between
patients with pathologic complete response (pCR) and patients with non-pCR. a Significantly elevated anti-HER2 CD4+ T cell responses by IFN-γ
enzyme-linked immunosorbent spot analysis (ELISPOT) are observed in patients with HER2pos invasive breast cancer achieving pCR (n = 16)
following neoadjuvant trastuzumab and chemotherapy (T + C), compared with patients with non-pCR (n = 24). Peripheral blood mononuclear
cells (PBMC) from patients with pCR and non-pCR were stimulated ex vivo with six HER2-derived class II peptides and IFN-γ production via
ELISPOT was compared. Responses are stratified by anti-HER2 responsivity, repertoire, and cumulative response. b Evaluable HLA-A2.1pos PBMC
from patients with pCR (n = 6; black bars) and non-pCR (n = 4; white bars) were stimulated ex vivo with two HER2-derived class I peptides,
HER2369–377 and HER2689–697, and IFN-γ production via ELISPOT was compared. Phorbol-12-myristate 13-acetate (PMA) and ionomycin served as
positive control. Results are expressed as mean spot-forming cells (SFC)/2 × 105 cells ± standard error of the mean
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anti-HER2 IFN-γ+ CD4+ T cell deficit
In order to ascertain the CD4+ T cell phenotype most
contributory to the anti-HER2 IFN-γ+ immune deficit,
HER2-stimulated PBMC were assessed for co-expression
of T-bet (Th1 transcription factor [16]) or GATA-3 (Th2
transcription factor [17]), and intracellular IFN-γ by flow
cytometry. Patients with pCR demonstrated a significantly
greater proportion of HER2-specific CD4+T-bet+IFN-γ+
(0.25 ± 0.1 % vs 0.02 ± 0.01 %, p = 0.039), but not
CD4+GATA-3+IFN-γ+ (0.02 ± 0.01 % vs 0.03 ± 0.01 %,
p = 0.49) or CD4+GATA-3+IFN-γ− (0.24 ± 0.03 % vs
0.27 ± 0.03 %, p = 0.52) PBMC, compared with patients
with non-pCR (Fig. 4a).
To determine the functional contribution of Th2 and
Treg phenotypes, HER2-specific IL-4 and IL-10 production
were examined via ELISPOT, respectively. While overall
anti-HER2 IL-4pos responsivity, repertoire, and cumulative
response did not differ between pCR and non-pCR
cohorts, donor-matched HER2-specific IFN-γ:IL-4 pro-
duction ratios shifted from 2.8:1 (relative Th1-favoring
phenotype) in pCR to 0.5:1 (relative Th2-favoring) innon-pCR patients (p <0.001; Fig. 4b). Similarly, overall
anti-HER2 IL-10pos immune metrics did not differ between
pCR and non-pCR patients; however, relative anti-HER2
IFN-γ:IL-10 contributions shifted from 1.6:1 (Th1-favor-
ing) in pCR to 0.3:1 (Treg-favoring) in non-pCR patients
(p = 0.008; Fig. 4c).
Th1 deficit in patients with non-pCR is unrelated to
immune incompetence, host-level T cell anergy or
immunosuppressive phenotypes
Immune competence in pCR and non-pCR subgroups
was assessed by anti-CD3/anti-CD28-stimulated Th1
responses using IFN-γ ELISPOT. Mean anti-CD3/
CD28 responses did not differ (1195 ± 87.4 vs 1085 ±
70.7 SFC/2 × 105 cells, p = 0.23) between pCR and
non-pCR cohorts. Furthermore, IFN-γ production
following recall stimuli (tetanus toxoid (105 ± 20.9 vs
98 ± 11.6 SFC/2 × 105), and Candida albicans (182 ± 29.8
vs 181 ± 9.0 SFC/2 × 105)) were similar between pCR
and non-pCR groups, respectively (Fig. 5a). Collectively,
these data suggest that the anti-HER2 Th1 disparity is
not attributable to host-level T cell anergy or impaired
Table 2 Univariate comparison of demographic and tumor-related characteristics between pCR and non-pCR patients
Characteristic Patients with pCR, number (%) or median (IQR) Patients with non-pCR, number (%) or median (IQR) P value
Overall population 16 (40) 24 (60) –
Age (years), median 45.5 (35.5–51.5) 49.5 (34.3–53.0) 0.97
BMI (kg/m2), median 25.7 (23.3–29.6) 27.3 (24.2–31.0) 0.49
Race 0.63
White 15 (93.8) 20 (83.3)
Black/Asian/Hispanic 1 (6.2) 4 (16.7)
Charlson comorbidity index 0.75
<2 (mild) 7 (43.8) 9 (37.5)
≥2 (moderate–high) 9 (56.2) 15 (62.5)
Menopausal status 1.00
Premenopausal 9 (56.2) 14 (58.3)
Postmenopausal 7 (43.8) 10 (41.7)
AJCC clinical stageb 0.12
II 11 (68.8) 10 (41.7)
III 5 (31.2) 14 (58.3)
ER/PR statusb 0.02
Positive 5 (31.2) 17 (70.8)
Negative 11 (68.8) 7 (29.2)
Lymphovascular invasion 0.21
Absent 15 (93.8) 18 (75.0)
Present 1 (6.2) 6 (25.0)
Nuclear grade 0.33
Grade 1/2 4 (25.0) 10 (41.7)
Grade 3 12 (75.0) 14 (58.3)
Neoadjuvant regimen 1.00
AC/TH 13 (81.3) 20 (83.3)
Othera 3 (18.7) 4 (16.7)
Operative approachb 0.09
BCS + XRT 8 (50.0) 5 (20.8)
Mastectomy ± XRT 8 (50.0) 19 (79.2)
aOther included carboplatin/taxotere/trastuzumab and taxotere/cyclophosphamide/trastuzumab. bIncluded in multivariable logistic regression analysis to
determine independent correlates to pCR. pCR pathologic complete response, BMI body mass index, AJCC American Joint Committee on Cancer, ER estrogen
receptor, PR progesterone receptor, AC/TH Adriamycin/Cytoxan/Taxol/Herceptin, BCS breast-conserving surgery, XRT radiotherapy
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PBMC.
On flow cytometry, the mean proportion of CD3+CD4+
(69.6 ± 6.2 % vs 68.5 ± 3.1 %, p = 0.87) and CD3+CD8+
(23.5 ± 4.5 % vs 25.9 ± 2.9 %, p = 0.67) cells did not differ
between PBMCs from pCR and non-pCR patients,
respectively (Fig. 5b). Proportions of B cells (CD19+) and
natural killer (NK) cells (CD3−CD16+) were similar
between groups (data not shown). Circulating immuno-
suppressive phenotypes were compared: mean propor-
tions of CD4+CD25+FoxP3+ cells (Treg) (0.95 ± 0.5 %
vs 0.88 ± 0.3 %, p = 0.89), and CD11b+CD33+HLA-
DR−CD83− cells (myeloid-derived suppressor cells(MDSC)) (0.6 ± 0.1 % vs 0.9 ± 0.3 %, p = 0.34) did
not differ between pCR and non-pCR subgroups,
respectively (Fig. 5c).
Anti-HER2 Th1 deficit in patients with non-pCR can be
corrected with HER2-targeted CD4+ Th1 immune
interventions
We have previously demonstrated that intranodally injected
HER2-pulsed DC1s elaborate abundant IL-12p70 and
polarize naïve CD4+ T-cells to IFN-γ/TNF-α-produ-
cing anti-HER2 Th1 in vivo [12, 18]. When employed in
HER2pos ductal carcinoma in situ (DCIS) and patients
with stage I HER2pos IBC in phase I/II trials, autologous
Fig. 4 Anti-human epidermal growth factor receptor 2 (anti-HER2) CD4+ T-helper type-1 (Th1) is the dominant phenotype contributing to
interferon-γ+ (IFN-γ+) CD4+ T cell deficit in patients without pathologic complete response (non-pCR). a Relative contributions of Th1 (T-bet+IFN-γ+)
versus Th2 (GATA-3+IFN-γ+) phenotypes to HER2 peptide-specific IFN-γ+ cells in peripheral blood mononuclear cells (PBMC) from pCR and
non-pCR patients. Representative stains within groups are shown after gating on CD4+ cells; results in adjoining histograms are expressed as
mean proportions (%) ± standard error of the mean (SEM) as indicated. b Circulating HER2-specific IL-4 production does not vary between pCR
and non-pCR patients, when assessed by responsivity, repertoire, and cumulative response. Results expressed as proportion or mean ± SEM (top
panel). Donor-matched cumulative IFN-γ and IL-4 production (spot-forming cells (SFC)/106 cells) across six HER2 class II peptides compared in pCR
and non-pCR patients. Relative HER2-specific IFN-γ:IL-4 proportions (% depicted in graph) was significantly higher in pCR (IFN-γ/(IFN-γ + IL-4) =
73.9 %:IL-4/(IFN-γ + IL-4) = 26.1 %) compared with non-pCR patients (34.6 %:65.4 %). Absolute IFN-γ:IL-4 production ratio changed from 2.8:1 (pCR)
to 0.5:1 (non-pCR) (bottom left panel). No relative shifts in IFN-γ:IL-4 production were observed to positive controls (anti-CD3/CD28 or anti-CD3,
respectively) (bottom right panel). c HER2-specific IL-10 production is similar between pCR and non-pCR patients across all Th1 metrics. Results are
expressed as proportion or mean ± SEM (top panel). Relative HER2-specific IFN-γ:IL-10 production was significantly higher in pCR (62.0:38.0 %)
compared with non-pCR (23.8:76.2 %) patients. Absolute IFN-γ:IL-10 production ratio changed from 1.6:1 (pCR) to 0.3:1 (non-pCR) (bottom left
panel). No relative shifts in IFN-γ:IL-4 production were observed to positive controls (anti-CD3/CD28 or anti-CD3, respectively) (bottom right panel);
*p <0.05, ** p <0.01, *** p <0.001
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Fig. 5 Anti-human epidermal growth factor receptor 2 (anti-HER2) T-helper type-1 (Th1) deficit in patients without pathologic complete response
(non-pCR) is not attributable to lack of immune competence, host-level T cell anergy, or increase in immunosuppressive phenotypes. Peripheral
blood mononuclear cells (PBMC) from pCR and non-pCR patients did not differ significantly in (a) immune competence – measured by IFN-γ
production to anti-CD3/anti-CD28 stimulus or recall stimuli tetanus toxoid and Candida albicans – by enzyme-linked immunosorbent spot. Results
presented as median ± IQR interferon-γ (IFN-γ) spot-forming cells (SFC)/2 × 105 cells. b, c Relative proportions of CD3+CD4+ (b, top) or CD3+CD8+
T-cells (b, bottom), Treg (CD4
+CD25+FoxP3+) (c, top) or myeloid-derived suppressor cells (MDSC) (CD11b+CD33+HLA-DR−CD83−) (c, bottom) by flow
cytometry. Representative stains within groups are shown; results in histograms are expressed as mean proportions (%) ± standard error of the
mean as indicated
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anti-HER2 Th1 immunity; pCR rates approached 25 %
with substantial loss of target antigen in the remainder of
patients (unpublished data) [15, 19].
In order to determine the impact of HER2-Th1-
targeted immune interventions in high-risk non-pCR
patients, four non-pCR patients (cohort G; Fig. 1) were
recruited to our phase I adjuvant HER2-pulsed DC1
vaccination trial (NCT02061423); demographic and
clinicopathologic characteristics of enrolled patients are
detailed in Table 3. Subjects received six weekly injections
followed by three booster doses at three-month inter-
vals. Vaccination-induced anti-HER2 Th1 responses were
followed prospectively; Th1 reactivity in individual patients
pre-vaccination and post-vaccination is illustrated in Fig. 6a.
In vaccinated subjects, evaluable anti-HER2 Th1 responses
measured 6 months post-vaccination (i.e., prior to the third
booster) indicated significantly improved anti-HER2 Th1
repertoire (3.7 ± 0.5 post-vaccination vs 0.5 ± 0.5 pre-
vaccination, p = 0.014) and cumulative response (192.3 ±
16.4 vs. 33.9 ± 19.4 SFC/106, p = 0.014) compared with
pre-vaccination levels (Fig. 6b). Vaccinations were well-
tolerated, with only two cases of grade-1 toxicity observed.Discussion
In the present study, we identify a novel systemic immune
correlate to pathologic response following neoadjuvant
HER2-targeted therapy in patients with HER2pos IBC.
Although not globally improved in all patients treated
with T + C, anti-HER2 CD4+ T-cell immunity is more
robust in patients achieving pCR compared with their
non-pCR counterparts despite controlling for relevant
demographic and tumor-related confounders. HER2-
specific Th1, but not Th2, CD4+ T-cells appear to be the
dominant contributor to the circulating anti-HER2
IFN-γ+ immune disparity; this anti-HER2 Th1 deficit
is not attributable to host-level T cell anergy, lack of
immunocompetence, or preponderance of immunosup-
pressive phenotypes in non-pCR patients. Importantly, this
anti-HER2 Th1 deficit is modifiable, and can be corrected
with HER2-pulsed DC1 vaccinations. In high-risk non-pCRTable 3 Demographic and clinicopathologic characteristics of patien
vaccination in HER2pos IBC patients with residual disease following n
Subject Age, y HLA Race Menopausal status ER
26113-01 67 A2 White Postmenopausal +, 30 %
26113-02 35 A2 White Premenopausal +, 30 %
26113-03 45 - White Premenopausal +, 84 %
26113-04 55 - White Postmenopausal −, 0 %
HER2 human epidermal growth factor receptor 2, DC1 type 1-polarized dendritic ce
ER estrogen receptor, PR progesterone receptor, T + C trastuzumab and chemother
Taxol/Herceptin, MRM modified radical mastectomy, FISH fluorescence in situ hybridizatipatients, strategies to boost anti-HER2 Th1 immunity may
be of benefit.
Pathologic complete response following neoadjuvant
administration of HER2-targeted therapies is a reliable
surrogate for favorable long-term outcomes in HER2pos
BC [7, 8]; in fact, the Food and Drug Administration
(FDA) supports pCR as a trial endpoint for drug approval
[20]. Conversely, non-pCR portends a worse overall prog-
nosis. Recent investigation has elucidated tumor cell-level
mechanisms that account for suboptimal responses to
HER2-targeted therapies, including overexpression of
EGFR, cMYC, or ERBB3, and mutational loss of PTEN or
activation of PI3K [21]. Beyond these factors, and the
known association between ER negativity [8] – which is
not readily modifiable – and pCR, there is a relative void in
our understanding of host-level factors that impact
response to HER2-directed therapies. In the current study,
heightened circulating anti-HER2 CD4+ Th1 immune
responses correlate strongly with pCR; conversely, the
association of an anti-HER2 Th1 immune deficit with
non-pCR warranted a search for therapeutic strategies
that might correct this deficit. Fortunately, even in
these heavily pre-treated patients, the Th1 deficit did
not appear to be immunologically fixed and could be
rectified with appropriate HER2-directed Th1 interven-
tions. Thus, while a strategy such as withholding HER2-
targeted therapies in patients with negatively prognostic
tumor-level genetic alterations (e.g., PI3K mutations)
is impractical [22], augmenting the depressed anti-
HER2 Th1 immunity in non-pCR patients may be more
feasible as an adjunct to existing HER2-targeted therapies
to improve clinical outcomes.
CD4+ Th1 cells have emerged as critical components of
antitumor immunity. Via expression of T-bet and IFN-γ, Th1
cells indirectly mediate antitumor effects by enhancing CD8+
cytotoxic T-lymphocyte and NK cell function [23]. In
addition, via elaboration of IFN-γ and TNF-α, HER2-specific
Th1 cells – in synergism with trastuzumab-mediated HER2
blockade – directly promote senescence and apoptosis, as
well as HER2-specific CD8+ T cell targeting of HER2-
overexpressing tumors in vitro [10, 24]. Indeed, the associ-
ation between improved HER2369–377-specific CD8
+ T-cellts recruited to the ongoing phase I trial of HER2-pulsed DC1
eoadjuvant trastuzumab and chemotherapy (NCT02061423)
PR HER2 T + C regimen Surgery yp stage
+, 5 % 3+, >90 % AC/TH MRM T1b N2a
+, 4 % 2+, FISH + AC/TH MRM T2 N2a
-, 3 % 3+, >10 % AC/TH MRM Tis N0
-, 0 % 3+, >10 % TC MRM T1c N1mi
ll, IBC invasive breast cancer, HLA human leukocyte antigen (A2 yes/no),
apy, yp post-neoadjuvant pathologic stage, AC/TH Adriamycin/Cyclophosphamide/
on, TC Taxotere, Cyclophosphamide
Fig. 6 Depressed anti-human epidermal growth factor receptor 2 (anti-HER2) T-helper type-1 (Th1) immunity is restored following HER2-pulsed
type 1-polarized dendritic cell (DC1) immunization. a Anti-HER2 CD4+ T cell immune reactivity profiles in four patients with non-pCR (UPCC #
26113–01 to −04) undergoing HER2-pulsed DC1 vaccination in the ongoing phase I trial NCT02061423 are demonstrated at three time points:
pre-vaccination (black), 3 months post vaccination (gray), and 6 months post vaccination (white). For these time points, responses to individual
HER2-derived class II peptides (x-axis; p42, p98, p328, p776, p927, p1166) are graphed, with anti-CD3/CD28 serving as positive control. Anti-HER2
Th1 repertoire and cumulative responses at these time points are listed in adjoining tables. b Anti-HER2 Th1 repertoire (mean # of reactive
peptides) and cumulative response (mean total SFC/106 cells) increase progressively in patients with non-pCR at the 3-month and 6-month time
points. SFC spot-forming cells
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may reflect the ready availability of CD4+ T cell help. More-
over, a recent genomic analysis from the NCCTG-N9831
trial demonstrated a strong association between increased
relapse-free survival in adjuvant trastuzumab-treated
patients and a signature of immune function genes,
including IFN-γ and TNF-α [21]. In the present
study, a relative decay in circulating anti-HER2 T-bet
+IFN-γ+ (i.e., Th1), but not GATA-3+IFN-γ+ (i.e., Th2),
phenotypes is associated with persistence of HER2pos
tumors following neoadjuvant T + C. Taken together,
these data suggest that abrogation of immunologic,
particularly anti-HER2 Th1 function, may represent a
HER2pos tumor-driven mechanism to evade immune sur-
veillance during T + C treatment. Immune interventions
aimed at restoring anti-HER2 Th1 function may be
valuable in improving pathologic response following
neoadjuvant T + C.
In parallel with these observations, growing evidence
indicates that robust cellular immune responses in the
tumor microenvironment are associated with improved
outcomes in BC [25], particularly in HER2pos subtypes
[26]. Furthermore, an analysis from the GeparQuattro
trial suggested that tumor-infiltrating lymphocyte (TIL)
density correlates with pCR following neoadjuvant T + C;
for every 10 % increase in TIL levels, a 16 % increase in
pCR rates was observed [27]. The sizeable increase in
circulating anti-HER2 Th1 populations in pCR patients
in the present study may represent a systemic corollary to
such immune-related changes in the tumor microenviron-
ment, and lend further support to evidence that intact
immune functionality, in addition to HER2-signaling inhib-
ition, is critical in mediating antitumor effects following
T + C treatment [28]. What is not immediately evident
from our analysis, however, is whether the heightened
anti-HER2 Th1 responses in pCR patients represent
preservation of erstwhile immunity, or immune restoration
following T + C treatment. If the latter is true, these data
may further support immune restorative neoadjuvant inter-
ventions in order to improve pathologic response.
Other limitations merit discussion. First, given the
retrospective and exploratory nature of the study design,
the findings herein should be interpreted as hypothesis-
generating and warrant large-scale validation. Second,
despite minimal demographic/clinical variability between
treatment-naïve T + C - treated HER2pos - IBC cohorts, the
global lack of improvement in anti-HER2 Th1 responses
following T + C treatment must be interpreted with caution,
since these data were derived from an unpaired comparison
between independent patient samples. Finally, while encour-
aging, definitive conclusions regarding the immune restora-
tive impact of HER2-directed DC1 vaccination in high-risk
non-pCR patients, cannot be drawn until completion and
final reporting of this ongoing trial.The translational implications of these findings bear
emphasis. As discussed, they may justify addition of
HER2-targeted Th1 immune interventions to neoadju-
vant T + C regimens and/or in the adjuvant setting for
high-risk non-pCR subgroups. Moreover, in light of our
recent demonstration that depressed anti-HER2 Th1
immunity correlates with subsequent recurrence in
patients treated with adjuvant T + C [10], monitoring
high-risk patients with non-pCR for real-time fluctua-
tions in anti-HER2 Th1 immunity may complement
existing radiographic surveillance, and identify critical
opportunities for therapeutic intervention. Incorpor-
ation of anti-HER2 Th1 immune detection protocols in
future clinical trial design, particularly those investigat-
ing neoadjuvant HER2-targeted therapies, appears
justified.
Conclusions
In summary, this is the first description, to our know-
ledge, of a critical association between anti-HER2
CD4+ Th1 immunity and pCR following neoadjuvant
T + C in HER2pos IBC patients. Although our data
cannot confirm causality, the dramatic IFN-γ+ anti-
HER2 Th1 deficit observed in non-pCR patients follow-
ing neoadjuvant T + C raises the possibility that immune
rescue with HER2-Th1 interventions may complement
standard HER2-targeted strategies in improving out-
comes in these high-risk patients. While correction of
the anti-HER2 Th1 immune deficit has already been
observed in non-pCR patients recruited to our HER2-DC1
vaccination trial, longitudinal follow up and larger-scale
studies will establish if such immune manipulations
ultimately mitigate recurrence in such patients.
Additional file
Additional file 1: Figure S1. Representative interferon (IFN)-γ enzyme-
linked immunosorbent spot (ELISPOT) assay results/calculation. IFN-γ ELISPOT
results from a single representative pathological complete response (pCR) (left
panel) and non-pCR (right panel) patients' peripheral blood mononuclear cells
(PBMC) illustrate our method of calculating the T-helper type-1 (Th1) metrics
utilized herein. PBMC are plated in triplicate, and spot-forming cells (SFC)
following ex vivo human epidermal growth factor receptor (HER)2-derived
class II peptide stimulation (indicated as stimulus, i.e., peptide 42–56, 98–114,
328–345, 776–790, 927–941, 1166–1180) are analyzed by an automated plate
reader. Peptide-specificmean IFN-γ responsesaredeterminedafter subtracting
fromunstimulatedbackground (e.g., p42-56SFCminusunstimulatedSFC). In
the adjoining histograms that quantify the ELISPOT assays directly
above, corrected mean peptide-specific IFN-γ SFC are plotted. Response
to an individual peptide is considered positive/reactive if >20 SFC/2 ×
105 cells (red line). Th1 responsivity indicates whether a particular donor
demonstrated a positive/reactive response to any of the six tested
peptides - in this example, both the pCR and non-pCR patients were
responsive. Th1 repertoire represents the number of reactive peptides -
in this example, pCR donor: 4; non-pCR donor: 1. Th1 cumulative re-
sponse is determined by summing peptide-specific SFCs across all six
peptides, and standardizing to 106 cells - in this example, pCR donor:
197.5 SFC/106; non-pCR donor: 29.1 SFC/106. Mean IFN-γ SFC to anti-
CD3/anti-CD28 stimulus serves as positive control.
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